Protocol Ledger

Biopharma Industry · Consolidated Sponsor Hub

Genmab: Clinical Trials & FDA Approval Profile

Genmab (Global / Institutional) sponsors 49 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 29 active protocols (10 recruiting now), 1 completed protocols, and 0 all-time original FDA Drugs@FDA NDA and BLA approvals.

Primary Focus: Oncology and Hematology Interactive Workbench: Open Full Annual Timeline & Compare ->
Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)38.8%
Median Closed Enrollment vs National (145 pts)118 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for Genmab
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)49
Active Pipeline (Recruiting Now)29 (10)
Completed vs Stopped Early1 / 19 (38.8%)
Median Closed Actual Enrollment118 participants
Physical Hospital Site Disclosure88.6% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals0 (0 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With Genmab
Hospital Research SiteLocationShared Protocols
Clinica Universidad de NavarraPamplona, Navarre10
Hospital Universitario 12 de OctubreMadrid9
MD Anderson Cancer CenterHouston, TX9

Indexed Multi-Center Phase II & III Protocols

Representative ClinicalTrials.gov v2 Studies Sponsored by Genmab
NCT IdentifierProtocol Brief TitlePhaseStatus
NCT07604766An Extension Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant OPhase IIIRECRUITING
NCT07539311Study to Assess the Efficacy and Safety of Rina-S in Participants With Advanced Gastrointestinal (GI) CancersPhase IIRECRUITING
NCT07225270Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of ParticipanPhase IIIRECRUITING
NCT07288177Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung CancerPhase IIRECRUITING
NCT05578976A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, CyclophosphamiPhase IIIACTIVE NOT RECRUITING

Explore interactive annual charts and M&A subsidiary rollups in the Genmab Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI